RU2279893C2 - Фармацевтическая композиция для лечения фимоза путем местного применения кортикостероида - Google Patents
Фармацевтическая композиция для лечения фимоза путем местного применения кортикостероида Download PDFInfo
- Publication number
- RU2279893C2 RU2279893C2 RU2003119439/15A RU2003119439A RU2279893C2 RU 2279893 C2 RU2279893 C2 RU 2279893C2 RU 2003119439/15 A RU2003119439/15 A RU 2003119439/15A RU 2003119439 A RU2003119439 A RU 2003119439A RU 2279893 C2 RU2279893 C2 RU 2279893C2
- Authority
- RU
- Russia
- Prior art keywords
- pharmaceutical composition
- betamethasone
- treatment
- phimosis
- corticosteroids
- Prior art date
Links
- 238000011282 treatment Methods 0.000 title claims abstract description 67
- 239000003246 corticosteroid Substances 0.000 title claims abstract description 35
- 206010034878 phimosis Diseases 0.000 title claims description 64
- 239000008194 pharmaceutical composition Substances 0.000 title claims description 50
- 230000000699 topical effect Effects 0.000 title claims description 28
- UREBDLICKHMUKA-DVTGEIKXSA-N betamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-DVTGEIKXSA-N 0.000 claims abstract description 31
- 229960002537 betamethasone Drugs 0.000 claims abstract description 29
- 108010003272 Hyaluronate lyase Proteins 0.000 claims abstract description 24
- 102000001974 Hyaluronidases Human genes 0.000 claims abstract description 23
- 229960002773 hyaluronidase Drugs 0.000 claims abstract description 23
- 229960001334 corticosteroids Drugs 0.000 claims abstract description 22
- 150000003431 steroids Chemical class 0.000 claims abstract description 18
- 239000006071 cream Substances 0.000 claims abstract description 16
- 239000003814 drug Substances 0.000 claims abstract description 16
- 239000002674 ointment Substances 0.000 claims abstract description 14
- 230000003054 hormonal effect Effects 0.000 claims abstract description 13
- 239000000203 mixture Substances 0.000 claims abstract description 13
- 229940121363 anti-inflammatory agent Drugs 0.000 claims abstract description 8
- 239000002260 anti-inflammatory agent Substances 0.000 claims abstract description 8
- 239000000654 additive Substances 0.000 claims abstract description 6
- 239000000443 aerosol Substances 0.000 claims abstract description 3
- 239000000499 gel Substances 0.000 claims abstract description 3
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 claims description 16
- 239000002552 dosage form Substances 0.000 claims description 8
- 229960000890 hydrocortisone Drugs 0.000 claims description 8
- 230000002797 proteolythic effect Effects 0.000 claims description 8
- -1 buteprate Chemical compound 0.000 claims description 7
- CBGUOGMQLZIXBE-XGQKBEPLSA-N clobetasol propionate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CCl)(OC(=O)CC)[C@@]1(C)C[C@@H]2O CBGUOGMQLZIXBE-XGQKBEPLSA-N 0.000 claims description 7
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 claims description 6
- 229960004703 clobetasol propionate Drugs 0.000 claims description 5
- 229940070710 valerate Drugs 0.000 claims description 5
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 claims description 5
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 claims description 4
- 229960004648 betamethasone acetate Drugs 0.000 claims description 4
- AKUJBENLRBOFTD-QZIXMDIESA-N betamethasone acetate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)COC(C)=O)(O)[C@@]1(C)C[C@@H]2O AKUJBENLRBOFTD-QZIXMDIESA-N 0.000 claims description 4
- 229960001259 diclofenac Drugs 0.000 claims description 4
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 claims description 4
- 150000002148 esters Chemical class 0.000 claims description 4
- 229960004311 betamethasone valerate Drugs 0.000 claims description 3
- SNHRLVCMMWUAJD-SUYDQAKGSA-N betamethasone valerate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(OC(=O)CCCC)[C@@]1(C)C[C@@H]2O SNHRLVCMMWUAJD-SUYDQAKGSA-N 0.000 claims description 3
- FUFLCEKSBBHCMO-UHFFFAOYSA-N 11-dehydrocorticosterone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 FUFLCEKSBBHCMO-UHFFFAOYSA-N 0.000 claims description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims description 2
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 claims description 2
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 claims description 2
- MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 claims description 2
- MFYSYFVPBJMHGN-UHFFFAOYSA-N Cortisone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 MFYSYFVPBJMHGN-UHFFFAOYSA-N 0.000 claims description 2
- DYEFUKCXAQOFHX-UHFFFAOYSA-N Ebselen Chemical compound [se]1C2=CC=CC=C2C(=O)N1C1=CC=CC=C1 DYEFUKCXAQOFHX-UHFFFAOYSA-N 0.000 claims description 2
- WJOHZNCJWYWUJD-IUGZLZTKSA-N Fluocinonide Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)COC(=O)C)[C@@]2(C)C[C@@H]1O WJOHZNCJWYWUJD-IUGZLZTKSA-N 0.000 claims description 2
- POPFMWWJOGLOIF-XWCQMRHXSA-N Flurandrenolide Chemical compound C1([C@@H](F)C2)=CC(=O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O POPFMWWJOGLOIF-XWCQMRHXSA-N 0.000 claims description 2
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 claims description 2
- SBDNJUWAMKYJOX-UHFFFAOYSA-N Meclofenamic Acid Chemical compound CC1=CC=C(Cl)C(NC=2C(=CC=CC=2)C(O)=O)=C1Cl SBDNJUWAMKYJOX-UHFFFAOYSA-N 0.000 claims description 2
- CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 claims description 2
- 229940022663 acetate Drugs 0.000 claims description 2
- 239000002253 acid Substances 0.000 claims description 2
- 150000007513 acids Chemical class 0.000 claims description 2
- 229960003099 amcinonide Drugs 0.000 claims description 2
- ILKJAFIWWBXGDU-MOGDOJJUSA-N amcinonide Chemical compound O([C@@]1([C@H](O2)C[C@@H]3[C@@]1(C[C@H](O)[C@]1(F)[C@@]4(C)C=CC(=O)C=C4CC[C@H]13)C)C(=O)COC(=O)C)C12CCCC1 ILKJAFIWWBXGDU-MOGDOJJUSA-N 0.000 claims description 2
- 229960001102 betamethasone dipropionate Drugs 0.000 claims description 2
- CIWBQSYVNNPZIQ-XYWKZLDCSA-N betamethasone dipropionate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)COC(=O)CC)(OC(=O)CC)[C@@]1(C)C[C@@H]2O CIWBQSYVNNPZIQ-XYWKZLDCSA-N 0.000 claims description 2
- VQODGRNSFPNSQE-DVTGEIKXSA-N betamethasone phosphate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)COP(O)(O)=O)(O)[C@@]1(C)C[C@@H]2O VQODGRNSFPNSQE-DVTGEIKXSA-N 0.000 claims description 2
- 229950006991 betamethasone phosphate Drugs 0.000 claims description 2
- 229960002842 clobetasol Drugs 0.000 claims description 2
- SXYZQZLHAIHKKY-GSTUPEFVSA-N clocortolone pivalate Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(Cl)[C@@H]2[C@@H]2C[C@@H](C)[C@H](C(=O)COC(=O)C(C)(C)C)[C@@]2(C)C[C@@H]1O SXYZQZLHAIHKKY-GSTUPEFVSA-N 0.000 claims description 2
- 229960001357 clocortolone pivalate Drugs 0.000 claims description 2
- 229960004544 cortisone Drugs 0.000 claims description 2
- 229960003662 desonide Drugs 0.000 claims description 2
- WBGKWQHBNHJJPZ-LECWWXJVSA-N desonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O WBGKWQHBNHJJPZ-LECWWXJVSA-N 0.000 claims description 2
- 229960002593 desoximetasone Drugs 0.000 claims description 2
- VWVSBHGCDBMOOT-IIEHVVJPSA-N desoximetasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@H](C(=O)CO)[C@@]1(C)C[C@@H]2O VWVSBHGCDBMOOT-IIEHVVJPSA-N 0.000 claims description 2
- 229960004511 fludroxycortide Drugs 0.000 claims description 2
- 229960001347 fluocinolone acetonide Drugs 0.000 claims description 2
- FEBLZLNTKCEFIT-VSXGLTOVSA-N fluocinolone acetonide Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O FEBLZLNTKCEFIT-VSXGLTOVSA-N 0.000 claims description 2
- 229960000785 fluocinonide Drugs 0.000 claims description 2
- 229960002390 flurbiprofen Drugs 0.000 claims description 2
- SYTBZMRGLBWNTM-UHFFFAOYSA-N flurbiprofen Chemical compound FC1=CC(C(C(O)=O)C)=CC=C1C1=CC=CC=C1 SYTBZMRGLBWNTM-UHFFFAOYSA-N 0.000 claims description 2
- 229960001680 ibuprofen Drugs 0.000 claims description 2
- DKYWVDODHFEZIM-UHFFFAOYSA-N ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 claims description 2
- 229960000991 ketoprofen Drugs 0.000 claims description 2
- 229940013798 meclofenamate Drugs 0.000 claims description 2
- 229960002744 mometasone furoate Drugs 0.000 claims description 2
- WOFMFGQZHJDGCX-ZULDAHANSA-N mometasone furoate Chemical compound O([C@]1([C@@]2(C)C[C@H](O)[C@]3(Cl)[C@@]4(C)C=CC(=O)C=C4CC[C@H]3[C@@H]2C[C@H]1C)C(=O)CCl)C(=O)C1=CC=CO1 WOFMFGQZHJDGCX-ZULDAHANSA-N 0.000 claims description 2
- 229960002009 naproxen Drugs 0.000 claims description 2
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 claims description 2
- OFPXSFXSNFPTHF-UHFFFAOYSA-N oxaprozin Chemical compound O1C(CCC(=O)O)=NC(C=2C=CC=CC=2)=C1C1=CC=CC=C1 OFPXSFXSNFPTHF-UHFFFAOYSA-N 0.000 claims description 2
- 229960002739 oxaprozin Drugs 0.000 claims description 2
- 238000002360 preparation method Methods 0.000 claims description 2
- 229960000894 sulindac Drugs 0.000 claims description 2
- MLKXDPUZXIRXEP-MFOYZWKCSA-N sulindac Chemical compound CC1=C(CC(O)=O)C2=CC(F)=CC=C2\C1=C/C1=CC=C(S(C)=O)C=C1 MLKXDPUZXIRXEP-MFOYZWKCSA-N 0.000 claims description 2
- 229960003604 testosterone Drugs 0.000 claims description 2
- 229960001017 tolmetin Drugs 0.000 claims description 2
- UPSPUYADGBWSHF-UHFFFAOYSA-N tolmetin Chemical compound C1=CC(C)=CC=C1C(=O)C1=CC=C(CC(O)=O)N1C UPSPUYADGBWSHF-UHFFFAOYSA-N 0.000 claims description 2
- YNDXUCZADRHECN-JNQJZLCISA-N triamcinolone acetonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O YNDXUCZADRHECN-JNQJZLCISA-N 0.000 claims description 2
- 229960002117 triamcinolone acetonide Drugs 0.000 claims description 2
- 229910019142 PO4 Inorganic materials 0.000 claims 1
- 235000013832 Valeriana officinalis Nutrition 0.000 claims 1
- 244000126014 Valeriana officinalis Species 0.000 claims 1
- 229950007227 buteprate Drugs 0.000 claims 1
- 229960004154 diflorasone Drugs 0.000 claims 1
- WXURHACBFYSXBI-XHIJKXOTSA-N diflorasone Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@H](C)[C@@](C(=O)CO)(O)[C@@]2(C)C[C@@H]1O WXURHACBFYSXBI-XHIJKXOTSA-N 0.000 claims 1
- 229960001293 methylprednisolone acetate Drugs 0.000 claims 1
- PLBHSZGDDKCEHR-LFYFAGGJSA-N methylprednisolone acetate Chemical compound C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)COC(C)=O)CC[C@H]21 PLBHSZGDDKCEHR-LFYFAGGJSA-N 0.000 claims 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims 1
- 239000010452 phosphate Substances 0.000 claims 1
- 229960002702 piroxicam Drugs 0.000 claims 1
- QYSPLQLAKJAUJT-UHFFFAOYSA-N piroxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 QYSPLQLAKJAUJT-UHFFFAOYSA-N 0.000 claims 1
- 229950008396 ulobetasol propionate Drugs 0.000 claims 1
- BDSYKGHYMJNPAB-LICBFIPMSA-N ulobetasol propionate Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@H](C)[C@@](C(=O)CCl)(OC(=O)CC)[C@@]2(C)C[C@@H]1O BDSYKGHYMJNPAB-LICBFIPMSA-N 0.000 claims 1
- 235000016788 valerian Nutrition 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 6
- 230000006872 improvement Effects 0.000 abstract description 3
- 239000000126 substance Substances 0.000 abstract description 3
- 238000009472 formulation Methods 0.000 abstract 2
- 230000007721 medicinal effect Effects 0.000 abstract 1
- 210000003899 penis Anatomy 0.000 description 26
- 210000003953 foreskin Anatomy 0.000 description 25
- 229940079593 drug Drugs 0.000 description 13
- 102000004190 Enzymes Human genes 0.000 description 11
- 108090000790 Enzymes Proteins 0.000 description 11
- 229940088598 enzyme Drugs 0.000 description 11
- 238000001356 surgical procedure Methods 0.000 description 9
- 238000002347 injection Methods 0.000 description 8
- 239000007924 injection Substances 0.000 description 8
- 238000000034 method Methods 0.000 description 8
- 230000002344 fibroplastic effect Effects 0.000 description 7
- 230000006698 induction Effects 0.000 description 7
- 208000024891 symptom Diseases 0.000 description 7
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 5
- 208000032843 Hemorrhage Diseases 0.000 description 5
- 230000000740 bleeding effect Effects 0.000 description 5
- 229920002674 hyaluronan Polymers 0.000 description 5
- 229960003160 hyaluronic acid Drugs 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 208000032984 Intraoperative Complications Diseases 0.000 description 3
- 102000035195 Peptidases Human genes 0.000 description 3
- 108091005804 Peptidases Proteins 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 230000003110 anti-inflammatory effect Effects 0.000 description 3
- 210000002808 connective tissue Anatomy 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000008034 disappearance Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 230000036407 pain Effects 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 3
- 230000003637 steroidlike Effects 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 229940099259 vaseline Drugs 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 208000031481 Pathologic Constriction Diseases 0.000 description 2
- 208000004362 Penile Induration Diseases 0.000 description 2
- 208000020758 Peyronie disease Diseases 0.000 description 2
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 description 2
- 206010046451 Urethral fistula Diseases 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 208000034158 bleeding Diseases 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 230000007794 irritation Effects 0.000 description 2
- 229940126601 medicinal product Drugs 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 239000002480 mineral oil Substances 0.000 description 2
- 235000010446 mineral oil Nutrition 0.000 description 2
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 2
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 239000000902 placebo Substances 0.000 description 2
- 229940068196 placebo Drugs 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 230000001953 sensory effect Effects 0.000 description 2
- 230000036262 stenosis Effects 0.000 description 2
- 208000037804 stenosis Diseases 0.000 description 2
- 239000002294 steroidal antiinflammatory agent Substances 0.000 description 2
- 229940125379 topical corticosteroid Drugs 0.000 description 2
- 239000012049 topical pharmaceutical composition Substances 0.000 description 2
- 210000003708 urethra Anatomy 0.000 description 2
- 239000002023 wood Substances 0.000 description 2
- SGTNSNPWRIOYBX-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC=C(OC)C(OC)=C1 SGTNSNPWRIOYBX-UHFFFAOYSA-N 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 206010006784 Burning sensation Diseases 0.000 description 1
- 102000011022 Chorionic Gonadotropin Human genes 0.000 description 1
- 108010062540 Chorionic Gonadotropin Proteins 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010018852 Haematoma Diseases 0.000 description 1
- 206010020565 Hyperaemia Diseases 0.000 description 1
- 206010020649 Hyperkeratosis Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 241000208202 Linaceae Species 0.000 description 1
- 235000004431 Linum usitatissimum Nutrition 0.000 description 1
- 241000551546 Minerva Species 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 208000028938 Urination disease Diseases 0.000 description 1
- KXKVLQRXCPHEJC-UHFFFAOYSA-N acetic acid trimethyl ester Natural products COC(C)=O KXKVLQRXCPHEJC-UHFFFAOYSA-N 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000003470 adrenal cortex hormone Substances 0.000 description 1
- 238000002266 amputation Methods 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 239000008365 aqueous carrier Substances 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 238000003287 bathing Methods 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000011138 biotechnological process Methods 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 238000007905 drug manufacturing Methods 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000009931 harmful effect Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 229940084986 human chorionic gonadotropin Drugs 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000002690 local anesthesia Methods 0.000 description 1
- 230000008752 local inflammatory process Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 239000003182 parenteral nutrition solution Substances 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 229960004618 prednisone Drugs 0.000 description 1
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 1
- 239000000955 prescription drug Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 230000002784 sclerotic effect Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 238000011477 surgical intervention Methods 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 210000001179 synovial fluid Anatomy 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 239000006208 topical dosage form Substances 0.000 description 1
- 230000000472 traumatic effect Effects 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 229960001722 verapamil Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| BR0006556-0A BR0006556A (pt) | 2000-12-28 | 2000-12-28 | Composição farmacêutica para uso tópico à base de corticosteróide para tratamento de fimose |
| BRPI0006556-0 | 2000-12-28 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2003119439A RU2003119439A (ru) | 2005-02-27 |
| RU2279893C2 true RU2279893C2 (ru) | 2006-07-20 |
Family
ID=36686652
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2003119439/15A RU2279893C2 (ru) | 2000-12-28 | 2001-12-13 | Фармацевтическая композиция для лечения фимоза путем местного применения кортикостероида |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US7666858B2 (enExample) |
| EP (1) | EP1365766B1 (enExample) |
| JP (1) | JP5095907B2 (enExample) |
| CN (1) | CN1270719C (enExample) |
| AR (1) | AR032208A1 (enExample) |
| AU (1) | AU2002221365A1 (enExample) |
| BR (1) | BR0006556A (enExample) |
| DE (1) | DE60121047T2 (enExample) |
| ES (1) | ES2267671T3 (enExample) |
| MX (1) | MXPA03005813A (enExample) |
| RU (1) | RU2279893C2 (enExample) |
| WO (1) | WO2002053137A2 (enExample) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2569431C2 (ru) * | 2013-07-08 | 2015-11-27 | Александр Васильевич Газаматов | Способ консервативного лечения фимоза |
| RU2635460C2 (ru) * | 2010-06-17 | 2017-11-13 | Нитто Денко Корпорейшн | Средство для лечения фиброза почек |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20070134232A1 (en) * | 2005-12-14 | 2007-06-14 | Joel Studin | Topical bite care composition |
| US20070225670A1 (en) * | 2006-03-14 | 2007-09-27 | Connell Thomas J | Diapers for improving male genital health and methods of using the same |
| CA2678038C (en) * | 2007-02-15 | 2016-10-11 | Allergan, Inc. | Use of botulinum toxin and enzymes for treating bladder or prostate disorders, or hyperhydrosis |
| KR20130125753A (ko) * | 2010-07-20 | 2013-11-19 | 할로자임, 아이엔씨 | 항-히알루로난제 투여와 관련된 유해 부작용의 치료 |
| CN102302779A (zh) * | 2011-07-29 | 2012-01-04 | 岳中瑾 | 治疗包茎的乳膏制剂及其应用 |
| US10058542B1 (en) | 2014-09-12 | 2018-08-28 | Thioredoxin Systems Ab | Composition comprising selenazol or thiazolone derivatives and silver and method of treatment therewith |
| CN110314168A (zh) * | 2019-07-27 | 2019-10-11 | 清远市人民医院 | 一种用于治疗小儿包茎的药物组合物及其制备方法 |
| RU2730476C1 (ru) * | 2019-12-24 | 2020-08-24 | федеральное государственное бюджетное образовательное учреждение высшего образования "Ставропольский государственный аграрный университет" | Противовоспалительная мазь для животных |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2058780C1 (ru) * | 1992-11-17 | 1996-04-27 | Совместное русско-американское акционерное общество закрытого типа "Неофарм" | Средство, обладающее тонизирующим действием на гладкую мускулатуру вен, мочевого пузыря и предстательной железы |
-
2000
- 2000-12-28 BR BR0006556-0A patent/BR0006556A/pt active Search and Examination
-
2001
- 2001-12-13 DE DE60121047T patent/DE60121047T2/de not_active Expired - Lifetime
- 2001-12-13 ES ES01272567T patent/ES2267671T3/es not_active Expired - Lifetime
- 2001-12-13 JP JP2002554088A patent/JP5095907B2/ja not_active Expired - Fee Related
- 2001-12-13 WO PCT/BR2001/000154 patent/WO2002053137A2/en not_active Ceased
- 2001-12-13 MX MXPA03005813A patent/MXPA03005813A/es active IP Right Grant
- 2001-12-13 EP EP01272567A patent/EP1365766B1/en not_active Expired - Lifetime
- 2001-12-13 CN CNB01822296XA patent/CN1270719C/zh not_active Expired - Fee Related
- 2001-12-13 RU RU2003119439/15A patent/RU2279893C2/ru not_active IP Right Cessation
- 2001-12-13 AU AU2002221365A patent/AU2002221365A1/en not_active Abandoned
- 2001-12-13 US US10/465,977 patent/US7666858B2/en not_active Expired - Fee Related
- 2001-12-27 AR ARP010106081A patent/AR032208A1/es unknown
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2058780C1 (ru) * | 1992-11-17 | 1996-04-27 | Совместное русско-американское акционерное общество закрытого типа "Неофарм" | Средство, обладающее тонизирующим действием на гладкую мускулатуру вен, мочевого пузыря и предстательной железы |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2635460C2 (ru) * | 2010-06-17 | 2017-11-13 | Нитто Денко Корпорейшн | Средство для лечения фиброза почек |
| RU2711531C2 (ru) * | 2010-06-17 | 2020-01-17 | Нитто Денко Корпорейшн | Средство для лечения фиброза почек |
| RU2569431C2 (ru) * | 2013-07-08 | 2015-11-27 | Александр Васильевич Газаматов | Способ консервативного лечения фимоза |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1487833A (zh) | 2004-04-07 |
| MXPA03005813A (es) | 2005-02-14 |
| AR032208A1 (es) | 2003-10-29 |
| CN1270719C (zh) | 2006-08-23 |
| EP1365766B1 (en) | 2006-06-21 |
| BR0006556A (pt) | 2002-09-17 |
| JP2004519451A (ja) | 2004-07-02 |
| WO2002053137A2 (en) | 2002-07-11 |
| AU2002221365A1 (en) | 2002-07-16 |
| RU2003119439A (ru) | 2005-02-27 |
| DE60121047D1 (de) | 2006-08-03 |
| DE60121047T2 (de) | 2007-06-21 |
| ES2267671T3 (es) | 2007-03-16 |
| US20040067922A1 (en) | 2004-04-08 |
| HK1060850A1 (en) | 2004-08-27 |
| US7666858B2 (en) | 2010-02-23 |
| JP5095907B2 (ja) | 2012-12-12 |
| WO2002053137A3 (en) | 2003-04-24 |
| EP1365766A2 (en) | 2003-12-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Wilkinson et al. | Perioral dermatitis: a 12‐year review | |
| Charman et al. | The use of corticosteroids and corticosteroid phobia in atopic dermatitis | |
| US20080038219A1 (en) | Novel Composition for a Topical Skin Treatment Base and Medicated Applications Thereof | |
| US20020192273A1 (en) | Therapeutic patch useful for the treatment of hemorrhoids | |
| JP3402613B2 (ja) | 点眼剤 | |
| CN115869258A (zh) | 用于治疗干眼病的调配物 | |
| Ruzicka | Methylprednisolone aceponate* in eczema and other inflammatory skin disorders–a clinical update | |
| JPH11514999A (ja) | ビタミンｄおよびその誘導体による掻痒症治療 | |
| JPH09504294A (ja) | 耳、眼もしくは鼻の治療に使用されるロテプレドノールエタボナートの懸濁剤 | |
| JPH02501739A (ja) | ステロイドローション剤 | |
| RU2279893C2 (ru) | Фармацевтическая композиция для лечения фимоза путем местного применения кортикостероида | |
| US20120022019A1 (en) | Medicinal Steroids Cream And A Process To Make It | |
| US20190374554A1 (en) | Use of oxygenated cholesterol sulfates (ocs) to treat inflammatory skin disease and skin lesions | |
| KR101642537B1 (ko) | 푸시드산나트륨을 사용하고 생체중합체를 혼입한 약용 푸시드산 크림 및 이의 제조 방법 | |
| JP2001517621A (ja) | 局所用非ステロイド系抗炎症剤組成物 | |
| Holbrook et al. | Aqueous hydrocortisone mouthwash solution: clinical evaluation | |
| Smeenk | Contact allergy to bufexamac | |
| JP2011510907A (ja) | 尋常性ざ瘡の長期間の処置のためのアダパレンおよび過酸化ベンゾイルの使用 | |
| Rapaport et al. | Prolonged erythema after facial laser resurfacing or phenol peel secondary to corticosteroid addiction | |
| JP2000229884A (ja) | 皮膚外用剤 | |
| CA3065893A1 (en) | Compositions for the treatment of ischemic ulcers and stretch marks | |
| WO2016198997A1 (en) | A medicinal cream made using betamethasone valerate and incorporating bio-polymer and a process to make the same | |
| HK1060850B (en) | Pharmaceutical composition for treatment of phimosis using topical corticosteroid | |
| KIRYATI | The Present Status of the Adrenal Cortical Hormones as Therapeutic Agents in Oral Conditions | |
| Caron et al. | Radiolabelled adapalene is poorly absorbed after topical application of adapalene 0.1% gel |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | The patent is invalid due to non-payment of fees |
Effective date: 20131214 |